[go: up one dir, main page]

MA40902A - Vaccins hpv16 thérapeutiques - Google Patents

Vaccins hpv16 thérapeutiques

Info

Publication number
MA40902A
MA40902A MA040902A MA40902A MA40902A MA 40902 A MA40902 A MA 40902A MA 040902 A MA040902 A MA 040902A MA 40902 A MA40902 A MA 40902A MA 40902 A MA40902 A MA 40902A
Authority
MA
Morocco
Prior art keywords
therapeutic
vaccines
hpv16 vaccines
therapeutic hpv16
nucleic acid
Prior art date
Application number
MA040902A
Other languages
English (en)
Other versions
MA40902B1 (fr
Inventor
Evelien M Bunnik
Jerôme Hhv Custers
Selina Khan
Koen Oosterhuis
Gerrit Ch Scheper
Taco Gilles Uil
Original Assignee
Janssen Vaccines & Prevention Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52020908&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA40902(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Vaccines & Prevention Bv filed Critical Janssen Vaccines & Prevention Bv
Publication of MA40902A publication Critical patent/MA40902A/fr
Publication of MA40902B1 publication Critical patent/MA40902B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20071—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Otolaryngology (AREA)

Abstract

L 'invention concerne des constructions d' acides nucléiques et des polypeptides de concepteur pouvant être utilisés en tant que vaccins thérapeutiques contre hpv16.
MA40902A 2014-11-04 2015-11-03 Vaccins hpv16 thérapeutiques MA40902B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14191660 2014-11-04
PCT/EP2015/075516 WO2016071306A1 (fr) 2014-11-04 2015-11-03 Vaccins thérapeutiques contre le vph16
EP15791556.2A EP3215187B1 (fr) 2014-11-04 2015-11-03 Vaccins hpv16 thérapeutiques

Publications (2)

Publication Number Publication Date
MA40902A true MA40902A (fr) 2017-09-13
MA40902B1 MA40902B1 (fr) 2018-12-31

Family

ID=52020908

Family Applications (2)

Application Number Title Priority Date Filing Date
MA046378A MA46378A (fr) 2014-11-04 2015-11-03 Vaccins hpv16 thérapeutiques
MA40902A MA40902B1 (fr) 2014-11-04 2015-11-03 Vaccins hpv16 thérapeutiques

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA046378A MA46378A (fr) 2014-11-04 2015-11-03 Vaccins hpv16 thérapeutiques

Country Status (34)

Country Link
US (4) US9701721B2 (fr)
EP (2) EP3421046A1 (fr)
JP (2) JP6325751B2 (fr)
KR (1) KR20170083562A (fr)
CN (1) CN107075521B (fr)
AR (1) AR102527A1 (fr)
AU (2) AU2015341926B2 (fr)
BR (1) BR112017009177A2 (fr)
CA (1) CA2965562C (fr)
CL (1) CL2017001089A1 (fr)
CO (1) CO2017004838A2 (fr)
CY (1) CY1121377T1 (fr)
DK (1) DK3215187T3 (fr)
EA (1) EA035461B1 (fr)
ES (1) ES2697903T3 (fr)
HR (1) HRP20181895T1 (fr)
HU (1) HUE040440T2 (fr)
IL (1) IL251895B (fr)
LT (1) LT3215187T (fr)
MA (2) MA46378A (fr)
MD (1) MD3215187T2 (fr)
MX (1) MX379069B (fr)
MY (1) MY181175A (fr)
NZ (1) NZ730802A (fr)
PL (1) PL3215187T3 (fr)
PT (1) PT3215187T (fr)
RS (1) RS58080B1 (fr)
SA (1) SA517381457B1 (fr)
SG (1) SG11201702997YA (fr)
SI (1) SI3215187T1 (fr)
SM (1) SMT201800602T1 (fr)
TW (2) TWI731654B (fr)
WO (1) WO2016071306A1 (fr)
ZA (1) ZA201703055B (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3215187T1 (sl) 2014-11-04 2019-02-28 Janssen Vaccines & Prevention B.V. Terapevtska cepiva HPV16
EP3337500A1 (fr) 2015-08-20 2018-06-27 Janssen Vaccines & Prevention B.V. Vaccins thérapeutiques contre le vph 18
EP3452087A1 (fr) * 2016-05-02 2019-03-13 Janssen Vaccines & Prevention B.V. Combinaisons thérapeutiques de vaccins contre le hpv
CN106632694B (zh) * 2017-01-24 2021-02-12 南京益康生物医药有限公司 一种重组蛋白及药物组合物与应用
TW201923084A (zh) 2017-09-23 2019-06-16 德商百靈佳殷格翰維美迪加股份有限公司 副黏液病毒科(paramyxoviridae)表現系統
WO2019164970A1 (fr) * 2018-02-20 2019-08-29 Emory University Protéines hpv, anticorps, et leurs utilisations dans la gestion de la croissance cellulaire épithéliale anormale
KR20200130371A (ko) * 2018-03-12 2020-11-18 에스큐지 바이오테크놀로지스 컴퍼니 Hpv-연관 질환을 치료하는 방법
CN112437684A (zh) * 2018-07-20 2021-03-02 扬森疫苗与预防公司 以提高的生产率表达寨卡抗原的重组腺病毒载体
CN108939064B (zh) * 2018-08-06 2021-12-10 南京颂悦生物科技有限公司 基于重组减毒绵羊李斯特菌的宫颈癌治疗性疫苗
CN108992665B (zh) * 2018-08-06 2021-11-19 南京颂悦生物科技有限公司 基于重组减毒单增李斯特菌的宫颈癌治疗性疫苗
JP2022523564A (ja) 2019-03-04 2022-04-25 アイオーカレンツ， インコーポレイテッド 機械学習を使用するデータ圧縮および通信
CN114555129A (zh) 2019-09-20 2022-05-27 特兰斯吉恩股份有限公司 编码hpv多肽和il-2的痘病毒与抗pd-l1抗体的组合
WO2021202949A2 (fr) * 2020-04-02 2021-10-07 Inovio Pharmaceuticals, Inc. Compositions et méthodes pour le traitement d'une dysplasie vulvaire
EP4135757A1 (fr) 2020-04-13 2023-02-22 Janssen Biotech, Inc. Vaccins à base de psma et de steap1 et leurs utilisations
EP4149530A1 (fr) * 2020-05-12 2023-03-22 Janssen Vaccines & Prevention B.V. Administration de vecteurs adénoviraux homologues
WO2022115490A2 (fr) * 2020-11-24 2022-06-02 MA, Muchou, Joe Vaccin à adn contre le papillomavirus humain et son procédé d'utilisation
CA3235779A1 (fr) * 2021-10-22 2023-04-27 Jian Yan Compositions et procedes de traitement d'une lesion intra-epitheliale squameuse de haut grade (hsil) anale
CN118344491B (zh) * 2024-05-03 2025-02-14 华中科技大学同济医学院附属同济医院 一种hpv16/18治疗性疫苗、制备方法和应用

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0173552B1 (fr) 1984-08-24 1991-10-09 The Upjohn Company Composés recombinants d'ADN et l'expression de polypeptides comme le tPA
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
WO1990014837A1 (fr) 1989-05-25 1990-12-13 Chiron Corporation Composition d'adjuvant comprenant une emulsion de gouttelettes d'huile d'une taille inferieure au micron
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
US5851806A (en) 1994-06-10 1998-12-22 Genvec, Inc. Complementary adenoviral systems and cell lines
JP3816518B2 (ja) 1994-06-10 2006-08-30 ジェンベク、インコーポレイティッド 相補的なアデノウイルスベクター系と細胞系
US5559099A (en) 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
US5965541A (en) 1995-11-28 1999-10-12 Genvec, Inc. Vectors and methods for gene transfer to cells
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
ATE445705T1 (de) 1995-06-15 2009-10-15 Crucell Holland Bv Verpackungssysteme für humane rekombinante adenoviren zur gentherapie
US5837511A (en) 1995-10-02 1998-11-17 Cornell Research Foundation, Inc. Non-group C adenoviral vectors
US5891690A (en) 1996-04-26 1999-04-06 Massie; Bernard Adenovirus E1-complementing cell lines
JP2000509614A (ja) 1997-03-04 2000-08-02 バクスター インターナショナル インコーポレイテッド アデノウイルスｅ１−相補性細胞系
US6020191A (en) 1997-04-14 2000-02-01 Genzyme Corporation Adenoviral vectors capable of facilitating increased persistence of transgene expression
US5972650A (en) 1997-06-26 1999-10-26 Brigham And Women's Hospital Tetracycline repressor regulated mammalian cell transcription and viral replication switch
US5981225A (en) 1998-04-16 1999-11-09 Baylor College Of Medicine Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same
US6113913A (en) 1998-06-26 2000-09-05 Genvec, Inc. Recombinant adenovirus
NZ515582A (en) 1999-05-17 2003-11-28 Crucell Holland B Adenovirus derived gene delivery vehicles comprising at least one element of adenovirus type 35
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
FR2794370B1 (fr) 1999-06-03 2003-10-17 Biovector Therapeutics Fragments proteiques polyepitopiques, leur obtention et leurs utilisations notamment en vaccination
EP1214097B3 (fr) * 1999-09-16 2011-07-20 Eisai Inc. Acides nucleiques codant pour des polypeptides de polyepitopes
DE19955558C2 (de) 1999-11-18 2003-03-20 Stefan Kochanek Permanente Amniozyten-Zelllinie, ihre Herstellung und Verwendung zur Herstellung von Gentransfervektoren
CA2425152A1 (fr) 2000-10-04 2002-04-11 The Trustees Of The University Of Pennsylvania Genes hautement exprimables
KR20090057335A (ko) 2000-11-23 2009-06-04 버베리안 노딕 에이/에스 변형된 백시니아 앙카라 바이러스 변형체
DE60234824D1 (de) 2001-05-01 2010-02-04 Ca Nat Research Council Induzierbares expressionssystem in eukaryotischen zellen
JP4495587B2 (ja) 2002-04-25 2010-07-07 クルセル ホランド ベー ヴェー 組換えアデノウイルスベクターおよびその使用
SE0202110D0 (sv) 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
SE0301998D0 (sv) 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof
WO2005089164A2 (fr) * 2003-12-31 2005-09-29 Pharmexa Inc. Induction de reponses immunitaires cellulaires au papillomavirus humain utilisant des compositions peptidiques et d'acides nucleiques
WO2005080556A2 (fr) 2004-02-23 2005-09-01 Crucell Holland B.V. Procedes de purification de virus
BRPI0517380A (pt) 2004-11-08 2008-10-07 Chromagenics Bv molécula de dna, cassete de expressão, célula hospedeira, e, métodos para gerar uma célula hospedeira que expressa um polipeptìdeo de interesse e para produzir um polipeptìdeo de interesse
WO2007073513A2 (fr) 2005-11-10 2007-06-28 Genvec, Inc. Procede de propagation de vecteurs adenoviraux codant pour des produits geniques inhibiteurs
DK1996238T3 (da) 2006-02-28 2016-08-01 Vaxart Inc Kimæriske adenovirale vektorer og DsRNA som TLR3-agonist
WO2007104792A2 (fr) 2006-03-16 2007-09-20 Crucell Holland B.V. Adénovirus recombinés basés sur les sérotypes 26 et 48 et utilisation de ceux-ci
EP2118292B1 (fr) * 2007-01-30 2011-08-03 Transgene SA Utilisation de polypeptide E2 de papillomavirus pour la vaccination
DE102008010954A1 (de) * 2008-02-25 2009-08-27 Cichon, Günter, Prof.Dr. DNA-Vakzine zur Therapie und Prophylaxe von Gebärmutterhalskrebs und seinen prämalignen Vorstufen
DK2350268T3 (en) 2008-11-03 2015-03-23 Crucell Holland Bv PROCEDURE FOR PRODUCING ADENOVIRUS VECTORS
GB0823497D0 (en) 2008-12-24 2009-01-28 Isis Innovation Immunogenic composition and use thereof
EP2536829B1 (fr) 2010-02-15 2016-04-06 Crucell Holland B.V. Procédé de production de vecteurs adénoviraux Ad26
US9000139B2 (en) * 2010-08-13 2015-04-07 Genexine, Inc. Composition for preventing or treating cervical cancer having human papillomavirus plasmodium and immunity enhancer
EP2780034A1 (fr) 2011-11-14 2014-09-24 Crucell Holland B.V. Immunisation primovaccination-rappel hétérologue à l'aide de vaccins à base du virus de la rougeole
EP2601968A1 (fr) * 2011-12-06 2013-06-12 Deutsches Krebsforschungszentrum Acides polynucléiques dérivés du VPH pour thérapie
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
US9119813B2 (en) 2012-03-22 2015-09-01 Crucell Holland B.V. Vaccine against RSV
KR102736868B1 (ko) 2014-09-03 2024-12-02 버베리안 노딕 에이/에스 재조합 변형된 백시니아 바이러스 앙카라 (mva) 필로바이러스 백신
SI3215187T1 (sl) 2014-11-04 2019-02-28 Janssen Vaccines & Prevention B.V. Terapevtska cepiva HPV16
EP3337500A1 (fr) * 2015-08-20 2018-06-27 Janssen Vaccines & Prevention B.V. Vaccins thérapeutiques contre le vph 18
EP3452087A1 (fr) * 2016-05-02 2019-03-13 Janssen Vaccines & Prevention B.V. Combinaisons thérapeutiques de vaccins contre le hpv

Also Published As

Publication number Publication date
JP2017534286A (ja) 2017-11-24
AU2015341926A1 (en) 2017-04-27
MY181175A (en) 2020-12-21
JP6325751B2 (ja) 2018-05-16
HUE040440T2 (hu) 2019-03-28
MX379069B (es) 2025-03-10
AU2018282463B2 (en) 2020-09-10
CN107075521B (zh) 2021-06-08
ES2697903T3 (es) 2019-01-29
US11040096B2 (en) 2021-06-22
JP6606571B2 (ja) 2019-11-13
TW201617450A (zh) 2016-05-16
KR20170083562A (ko) 2017-07-18
CO2017004838A2 (es) 2017-07-28
EP3215187B1 (fr) 2018-08-29
WO2016071306A1 (fr) 2016-05-12
MX2017005788A (es) 2017-08-02
AU2018282463A1 (en) 2019-01-24
TWI694147B (zh) 2020-05-21
EP3421046A1 (fr) 2019-01-02
US10071151B2 (en) 2018-09-11
DK3215187T3 (en) 2018-12-10
IL251895B (en) 2019-08-29
SI3215187T1 (sl) 2019-02-28
MA40902B1 (fr) 2018-12-31
JP2018148890A (ja) 2018-09-27
SA517381457B1 (ar) 2021-03-11
HRP20181895T1 (hr) 2019-01-11
PL3215187T3 (pl) 2019-04-30
IL251895A0 (en) 2017-06-29
TW202043476A (zh) 2020-12-01
PT3215187T (pt) 2018-11-27
CA2965562A1 (fr) 2016-05-12
US10555996B2 (en) 2020-02-11
LT3215187T (lt) 2018-12-27
EA035461B1 (ru) 2020-06-19
CN107075521A (zh) 2017-08-18
RS58080B1 (sr) 2019-02-28
CY1121377T1 (el) 2020-05-29
US20160122396A1 (en) 2016-05-05
EA201790976A1 (ru) 2017-09-29
TWI731654B (zh) 2021-06-21
US20170281747A1 (en) 2017-10-05
CA2965562C (fr) 2023-11-21
AR102527A1 (es) 2017-03-08
CL2017001089A1 (es) 2017-12-29
SG11201702997YA (en) 2017-05-30
MA46378A (fr) 2019-08-07
US9701721B2 (en) 2017-07-11
MD3215187T2 (ro) 2019-02-28
SMT201800602T1 (it) 2019-01-11
NZ730802A (en) 2021-12-24
ZA201703055B (en) 2019-11-27
US20200164057A1 (en) 2020-05-28
BR112017009177A2 (pt) 2018-12-11
EP3215187A1 (fr) 2017-09-13
AU2015341926B2 (en) 2018-09-27
US20180344841A1 (en) 2018-12-06

Similar Documents

Publication Publication Date Title
MA40902A (fr) Vaccins hpv16 thérapeutiques
PH12019501931A1 (en) Anti-pdl1 antibody formulations
CY1124407T1 (el) Ενωσεις αναστολεα αυτοταξινης
CY1124131T1 (el) Συζευγματα αντι-ρτκ7 αντισωματος-φαρμακου
BR112018003019A2 (pt) vacinas terapêuticas contra hpv18
MA40938A (fr) Anticorps anti-cd79b et méthodes d'utilisation desdits anticorps
HUE057877T2 (hu) Vegyületek és készítmények terápiás szerek intracelluláris bejuttatására
EA201891317A2 (ru) Терапевтические мишени для коррекции гена дистрофина человека с помощью редактирования генов и способы их применения
MA40576B1 (fr) Anticorps et immunoconjugués anti-her2
MX2017003022A (es) Anticuerpos anti-cll-1 e inmunoconjugados.
MX2019013670A (es) Formulaciones de anticuerpos y proteinas.
MX2019004690A (es) Constructos de anticuerpos.
MY176855A (en) Anti-jagged1 antibodies and methods of use
MX2016015162A (es) Anticuerpos anti - gpc3 e inmunoconjugados.
MX2016014306A (es) Marcadores para terapia con lipoproteinas de alta densidad (hdl).
MX2017004473A (es) Formulaciones de betalactamasa y usos de las mismas.
MX2018016362A (es) Formulaciones de anticuerpo anti-cd19.
MX2017003121A (es) Formulaciones de anticuerpos.
EA201791454A1 (ru) Лекарственные формы для трансдермального введения
IL263574A (en) Calr and jak2 vaccine compositions
MX2020012893A (es) Formulaciones de proteinas.
CL2019002733A1 (es) Formulaciones de clorhidrato del ácido 1-amino-1-ciclopropanocarboxílico.
PH12017500602A1 (en) Methods for treating ocular conditions
MY190102A (en) Tolerogenic dna vaccine
EP3394099A4 (fr) Formulations d'anticorps anti-il-10 modifiés